<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590667</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/028711</org_study_id>
    <nct_id>NCT01590667</nct_id>
  </id_info>
  <brief_title>Effect of Litramine on Fat Excretion</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled, Crossover Clinical Investigation to Evaluate the Effect of Litramine on Fecal Fat Excretion in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the effect of Litramine on fecal fat excretion in healthy
      subjects, to provide more comprehensive and robust clinical evidence in its mode of action
      for the treatment of obesity and weight management through dietary fat binding.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between Litramine and placebo in changes of percentage fecal fat excretion after intervention</measure>
    <time_frame>7 days per intervention</time_frame>
    <description>The amount of fat excreted in the feces will be quantified by the near-infrared reflectance analysis (NIRA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Full blood count</measure>
    <time_frame>Approximately 45 days</time_frame>
    <description>Analysis of hemoglobin, hematocrit, erythrocytes, thrombocytes, and leucocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical chemistry</measure>
    <time_frame>Approximately 45 days</time_frame>
    <description>Liver function, renal function, protein metabolism, lipid metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Approximately 45 days</time_frame>
    <description>Sitting blood pressure and heart rate will be measured using standard devices</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Litramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 tablets 3 times daily (oral consumption, 30 minutes after meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 tablets 3 times daily (oral consumption, 30 minutes after meal)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Litramine</intervention_name>
    <description>2 tablets 3 times daily (oral consumption, 30 minutes after meal)</description>
    <arm_group_label>Litramine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 tablets 3 times daily (oral consumption, 30 minutes after meal)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 20-30 kg/m2

          -  Accustomed to 3 main meals/day

          -  Commitment to avoid the use of other weight management products during study

          -  Females' agreement to use appropriate birth control methods during the active study
             period

          -  Self-reported regular bowel movement (1-2 times per day)

          -  Subject declares in writing his/her consent to participate, understands requirements
             of the study and is willing to comply

        Exclusion Criteria:

          -  Known sensitivity to the ingredients of the device

          -  Diabetes mellitus (type 1 or 2)

          -  History or clinical signs of endocrine disorders

          -  Clinically relevant excursions of safety parameter

          -  Current use of anti-depressants

          -  Presence of acute or chronic gastrointestinal disease

          -  Uncontrolled hypertension (more than 160/110 mm Hg)

          -  Stenosis in the gastrointestinal tract

          -  Bariatric surgery

          -  Abdominal surgery within the last 6 months prior to enrollment

          -  History of eating disorders such as bulimia, anorexia nervosa within the past 12
             months

          -  Other serious organ or systemic diseases such as cancer

          -  Any medication that could influence gastrointestinal functions

          -  Pregnancy or nursing

          -  Any medication or use of products for the treatment of obesity within 6 weeks prior to
             enrolment

          -  History of abuse of drugs, alcohol or medication

          -  Presence of other factor(s) that, in the investigator's judgment, should preclude
             subject participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regina Busch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>analyze &amp; realize AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wei√üenseer Weg 111</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2012</study_first_submitted>
  <study_first_submitted_qc>May 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2012</study_first_posted>
  <last_update_submitted>July 25, 2012</last_update_submitted>
  <last_update_submitted_qc>July 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fat excretion</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

